Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
150 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
16-AA-0059
Characterization of Brain Amyloid-beta (A-beta) Retention During Wakefulness And Following Emergence From Sleep In Healthy Subjects
Completed Study; data analyses ongoing
18-40 Years
NIAAA
Alzheimer 16
000740-CH
A Phase 3 Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over with Congenital Adrenal Hyperplasia
Enrolling by Invitation
18-125 Years
NICHD
16
000687-I
VRC 322/DMID 21-0016: A Phase I, Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults
Participants currently recruited/enrolled
18-60 Years
NIAID
16
000686-CH
Intrathecal 2-Hydroxypropyl-Beta-Cyclodextrin for Neurological Decline in Patients with Niemann-Pick Disease Type C1
Participants currently recruited/enrolled
18-125 Years
NICHD
16
000665-DK
A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients with Familial Partial Lipodystrophy
Participants currently recruited/enrolled
18-125 Years
NIDDK
16
000644-C
Phase 1/1b Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
16
000460-I
A Randomized, Placebo-controlled Crossover Study to Assess the Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose
Completed Study; data analyses ongoing
16-69 Years
NIAID
16
000411-CC
A Feasibility Pilot Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults with Congenital Adrenal Hyperplasia.
Recruitment has not started
16-22 Years
CC
16
000406-AA
Addictions Neuroclinical Assessment
Enrolling by Invitation
18-125 Years
NIAAA
16
000277-C
Imaging and Biopsy of HIV-Infected Individuals Undergoing Analytic Treatment Interruption
Participants currently recruited/enrolled
18-125 Years
NCI
16
000241-CH
Phase II Trial of Liraglutide (Saxenda(R), Novo Nordisk) in Adolescents with Obesity After Sleeve Gastrectomy: A Pilot Open-Label Study
Participants currently recruited/enrolled
12-20 Years
NICHD
16
000183-I
An open-label single-arm Phase IIb study of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi in patients lacking suitable alternative treatment options
Participants currently recruited/enrolled
16-125 Years
NIAID
16
000123-CC
Evaluation of Atherosclerotic Plaques in Abdominal CT Studies
No longer recruiting/follow-up only
0-125 Years
CC
16
000115-C
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants with Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants with Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster D
Participants currently recruited/enrolled
18-125 Years
NCI
16
20-M-0157
PET Imaging of Cyclooxygenase in Participants with Major Depressive Disorder (MDD)
Participants currently recruited/enrolled
18-70 Years
NIMH
16
20-M-0082
Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Participants currently recruited/enrolled
18-99 Years
NIMH
Alzheimer
20-H-0141
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
Enrolling by Invitation
18-125 Years
NHLBI
16
20-DK-0079
A Randomized, Double-Blinded, Placebo-Controlled Study of REGN4661, A Leptin Receptor Agonist Antibody, In Patients with Generalized Lipodystrophy
No longer recruiting/follow-up only
12-125 Years
NIDDK
16
20-D-0131
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sj(SqrRoot)(Delta)gren's Syndrome; a Phase Ib-IIa Placebo-controlled Clinical Trial and Associated Mechanistic Studies
Participants currently recruited/enrolled
18-75 Years
NIDCR
16
20-D-0122
A Phase IIb, Open-label Dose-ranging Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 (encaleret) in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
No longer recruiting/follow-up only
16-125 Years
NIDCR
16
20-C-0098
A Phase 1/2, Open Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects with Advanced or Metastatic Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
16
20-C-0069
A First-In-Human Phase I Single-Agent Dose-Escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Participants currently recruited/enrolled
18-125 Years
NCI
16
20-C-0062
A phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Participants currently recruited/enrolled
18-125 Years
NCI
16
20-AG-0087
Ketone ester effects on biomarkers of brain metabolism and cognitive performance in cognitively intact adults (Bullet) 55 years old. A double-blinded randomized controlled clinical trial
Participants currently recruited/enrolled
55-125 Years
NIA
Alzheimer
19-M-0095
PET Imaging of Neuroinflammation in Neurodegenerative Diseases via a Novel TSPO Radioligand
Participants currently recruited/enrolled
18-125 Years
NIMH
Alzheimer
19-I-0140
A Phase 1 Evaluation of the Safety of Belimumab in People with Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
Participants currently recruited/enrolled
18-70 Years
NIAID
16
19-DK-0072
Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Participants currently recruited/enrolled
18-125 Years
NIDDK
16
19-C-0016
Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors
Participants currently recruited/enrolled
0-125 Years
NCI
16
19-C-0006
Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype
Participants currently recruited/enrolled
18-125 Years
NCI
16
19-AT-0089
Sensory Afferents for Deep Pressure Sensation
Completed Study; data analyses ongoing
18-50 Years
NCCIH
16
18-N-0083
ASPIRO: A Phase 1/2/3, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Linked Myotubular Myopathy (XLMTM) Patients
No longer recruiting/follow-up only
3-5 Years
NINDS
16
18-EI-0068
An Investigation of Vitamin A Palmitate Supplementation in Patients with Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
Participants currently recruited/enrolled
50-125 Years
NEI
16
18-EI-0067
An Investigation of Vitamin A Palmitate Supplementation in Patients with Age-Related Macular Degeneration (and without reticular pseudodrusen) and Delayed Dark Adaptation
Participants currently recruited/enrolled
50-125 Years
NEI
16
18-DA-N095
Just-In-Time Adaptive Interventions for Addictive Behaviors
Participants currently recruited/enrolled
18-75 Years
NIDA
16
18-DA-N053
Imaging Biomarker for Addiction Treatment Outcome
Participants currently recruited/enrolled
21-125 Years
NIDA
16
18-C-0080
Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled Trial
Completed Study; data analyses ongoing
5-125 Years
NCI
16
16-N-0170
Effects of Prism Adaption and rTMS on Brain Connectivity and Visual Representation
Completed Study; data analyses ongoing
18-75 Years
NINDS
16
16-N-0166
Deep Brain Stimulation Surgery for Treatment of Focal Hand Dystonia
Participants currently recruited/enrolled
22-125 Years
NINDS
16
16-N-0114
The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study
Participants currently recruited/enrolled
18-125 Years
NINDS
16
16-N-0072
A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy with Ex Vivo Generated Polyomavirus-Specific T-cells
Completed Study; data analyses ongoing
18-125 Years
NINDS
16
16-N-0064
Cholinergic Receptor Imaging in Dystonia
Completed Study; data analyses ongoing
18-125 Years
NINDS
16
16-N-0058
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Completed Study; data analyses ongoing
18-60 Years
NINDS
16
16-N-0055
The Pathological Basis of MRI Signal Changes in Multiple Sclerosis: A Longitudinal In Vivo-to-Postmortem Study
Participants currently recruited/enrolled
18-125 Years
NINDS
16
16-N-0041
Tumor Related Epilepsy
Participants currently recruited/enrolled
8-125 Years
NINDS
16
16-N-0031
An All-Night Functional Magnetic Resonance Imaging Sleep Study With Auditory Stimuli
Participants currently recruited/enrolled
18-34 Years
NINDS
16
16-I-0165
An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 (leniolisib) in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/p110 delta-activating mutat
No longer recruiting/follow-up only
12-75 Years
NIAID
16
16-I-0126
Genomic Response of Human Immune and Non-Immune Cells to Glucocorticoids
Completed Study; data analyses ongoing
18-64 Years
NIAID
16
16-I-0078
Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME study)
Participants currently recruited/enrolled
18-49 Years
NIAID
16
16-I-0065
Screening for Alpha Globin Deletions
Participants currently recruited/enrolled
18-39 Years
NIAID
16
16-I-0053
A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSVdeltaG-ZEBOV GP) for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebola Virus Exposure (PREPARE)
No longer recruiting/follow-up only
18-125 Years
NIAID
16
16-I-0039
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
Participants currently recruited/enrolled
18-50 Years
NIAID
16
16-I-0032
High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous Disease
No longer recruiting/follow-up only
4-65 Years
NIAID
16
16-HG-0156
The Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic Acidemia
Participants currently recruited/enrolled
0-125 Years
NHGRI
16
16-HG-0026
New Technology and Child Health
Participants currently recruited/enrolled
18-125 Years
NHGRI
16
16-HG-0017
Genomic Services Research Program
Participants currently recruited/enrolled
0-125 Years
NHGRI
16
16-H-0144
Impact of Elastin Mediated Vascular Stiffness on End Organs
Participants currently recruited/enrolled
3-85 Years
NHLBI
16
16-H-0132
CADASIL Disease Discovery
Completed Study; data analyses ongoing
18-100 Years
NHLBI
16
16-H-0129
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity
Completed Study; data analyses ongoing
18-39 Years
NHLBI
16
16-H-0085
Pilot Study to Evaluate the Effect of Fasting and Refeeding on T-Cell Fate
Completed Study; data analyses ongoing
21-37 Years
NHLBI
16
16-H-0074
Williams Syndrome (WS) and Supravalvular Aortic Stenosis (SVAS) DNA and Tissue Bank
Participants currently recruited/enrolled
0-85 Years
NHLBI
16
16-H-0063
Williams Syndrome Skin and Vascular Elasticity Study (WS-SAVE Study)
Completed Study; data analyses ongoing
1-70 Years
NHLBI
16
16-H-0019
High Image Matrix CT Reconstruction
Completed Study; data analyses ongoing
18-99 Years
NHLBI
16
16-EI-0169
A Pilot Study to Investigate Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis
Completed Study; data analyses ongoing
18-125 Years
NEI
16
16-EI-0134
Studies of the Natural History, Pathogenesis and Outcome of Ocular Disorders
Participants currently recruited/enrolled
0-125 Years
NEI
16
16-EI-0104
Clinical and Molecular Studies in Families with Inherited Eye Disease
Participants currently recruited/enrolled
4-125 Years
NEI
16
16-EI-0090
Natural History of Spinocerebellar Ataxia Type 7 (SCA7)
Participants currently recruited/enrolled
12-125 Years
NEI
16
16-EI-0046
Uveitis/Intraocular Inflammatory Disease Biobank (iBank)
No longer recruiting/follow-up only
8-125 Years
NEI
16
16-EI-0024
Rod and Cone Mediated Function in Retinal Disease
Participants currently recruited/enrolled
5-125 Years
NEI
16
16-E-0157
CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study)
Completed Study; data analyses ongoing
18-28 Years
NIEHS
16
16-E-0096
Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function
Participants currently recruited/enrolled
18-65 Years
NIEHS
16
16-E-0006
Investigating the Impact of Obesity on Pubertal Development in Girls
Participants currently recruited/enrolled
8-14 Years
NIEHS
16
16-DK-0173
MEASuRE: Metreleptin Effectiveness and Safety Registry
Participants currently recruited/enrolled
0-125 Years
NIDDK
16
16-DK-0143
Idiosyncratic Liver Injury Associated with Drugs (ILIAD): A Retrospective Study
Participants currently recruited/enrolled
18-125 Years
NIDDK
16
16-DK-0125
Evaluation of Adults with Endocrine-Related Conditions
Participants currently recruited/enrolled
18-100 Years
NIDDK
16
16-DK-0068
The Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and its Role in Metabolism
Participants currently recruited/enrolled
18-125 Years
NIDDK
16
16-DK-0038
A Randomized, Double Blind, Placebo-Controlled Study to Assess Efficacy, Safety and Tolerability of ISIS 304801 in Patients with Partial Lipodystrophy with an Open-Label Extension
Completed Study; data analyses ongoing
18-125 Years
NIDDK
16
16-DA-N140
Effects of a New Behavioral Intervention on Alcohol Craving and Drinking
Participants currently recruited/enrolled
21-65 Years
NIDA
16
16-DA-0080
A Novel Compound for Alcoholism Treatment: a Translational Strategy - Part II
Completed Study; data analyses ongoing
18-70 Years
NIDA
16
16-D-0040
Natural History of Craniofacial Anomalies and Developmental Growth Variants
Participants currently recruited/enrolled
2-125 Years
NIDCR
16
16-CH-0164
A Phase III Extension Study of Efficacy, Safety and Tolerability of Chronocort (Registered) in the Treatment of Congenital Adrenal Hyperplasia
Completed Study; data analyses ongoing
18-80 Years
NICHD
16
16-CH-0113
Evaluation of Children with Endocrine and Metabolic-Related Conditions
Participants currently recruited/enrolled
0-100 Years
NICHD
16
16-CH-0103
Evaluation of Patients with Genetic Disorders
Participants currently recruited/enrolled
0-125 Years
NICHD
16
16-CC-0168
Focus Groups to Determine Surrogates' Views Regarding Patient Preference Predictors
Completed Study; data analyses ongoing
18-90 Years
CC
16
16-CC-0162
Longitudinal Changes in the Oral and Gut Microbiome of Individuals with Alcohol Dependence
Completed Study; data analyses ongoing
18-125 Years
CC
16
16-CC-0149
Dopamine and Motor Learning in Cerebral Palsy
Participants currently recruited/enrolled
5-25 Years
CC
16
16-CC-0112
Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted with Cobicistat in Healthy Volunteers
Completed Study; data analyses ongoing
18-65 Years
CC
16
16-CC-0098
Pilot Study of Ultrasound Guided Focal Thermal Ablation of Prostate Cancer
Clinical hold/Recruitment or enrollment suspended
18-125 Years
CC
16
16-CC-0056
Analysis of A Tool to Assess Psycho Social Spiritual Healing: Cognitive Interviewing
Completed Study; data analyses ongoing
18-125 Years
CC
16
16-CC-0049
A Phase II Study Using LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment with Transarterial Embolization (TAE) Alone or Combined with Thermal Ablation
Enrolling by Invitation
18-125 Years
CC
16
16-CC-0001
Evaluation of MiSeq for Microbial Identification in Specimens
Enrolling by Invitation
2-125 Years
CC
16
16-C-0171
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
16
16-C-0154
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
16
16-C-0151
Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous System
Participants currently recruited/enrolled
18-125 Years
NCI
16
16-C-0138
Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell Therapy
Participants currently recruited/enrolled
18-99 Years
NCI
16
16-C-0135
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
No longer recruiting/follow-up only
18-125 Years
NCI
16
16-C-0131
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing Cancers
Participants currently recruited/enrolled
18-70 Years
NCI
16
16-C-0128
A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0121
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0107
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
16
16-C-0097
Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma
Completed Study; data analyses ongoing
2-21 Years
NCI
16
16-C-0094
A Phase 1/2 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (SCT)
No longer recruiting/follow-up only
18-125 Years
NCI
16
16-C-0092
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0088
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritonea
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0087
Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor in Combination with Cisplatin in Patients with Refractory Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0081
A Phase I Dose Escalation Trial of Re-Irradiation in Good Prognosis Recurrent Glioblastoma
No longer recruiting/follow-up only
18-125 Years
NCI
16
16-C-0076
Prospective Screening for Patient Specific Genotypes and Phenotypes that Influence Drug Dosing and Trial Selection in Cancer Patients
Enrolling by Invitation
18-125 Years
NCI
16
16-C-0073
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0066
Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Participants currently recruited/enrolled
18-125 Years
NCI
16
16-C-0062
A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0061
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Participants currently recruited/enrolled
18-125 Years
NCI
16
16-C-0060
A Phase 1b/2 Study of alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation
Participants currently recruited/enrolled
18-125 Years
NCI
16
16-C-0054
T Cells Expressing a Fully-human Anti- CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
No longer recruiting/follow-up only
18-73 Years
NCI
16
16-C-0048
Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
16
16-C-0047
A Phase 1 Trial of Pomalidomide in Combination with Liposomal Doxorubicin in Patients with Advanced or Refractory Kaposi Sarcoma
Participants currently recruited/enrolled
18-125 Years
NCI
16
16-C-0043
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
No longer recruiting/follow-up only
18-125 Years
NCI
16
16-C-0035
Prostvac in Patients with Biochemically Recurrent Prostate Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
16
16-C-0034
A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0027
A Prospective Randomized and Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Participants currently recruited/enrolled
18-70 Years
NCI
16
16-C-0011
A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0010
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
Participants currently recruited/enrolled
18-125 Years
NCI
16
16-C-0009
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0003
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Participants currently recruited/enrolled
4-75 Years
NCI
16
16-AT-0136
Effects of External Ear Stimulation on Pain Perception and Mood
Participants currently recruited/enrolled
18-50 Years
NCCIH
16
16-AT-0077
Clinical and Scientific Assessment of Pain and Painful Disorders
Participants currently recruited/enrolled
12-125 Years
NCCIH
16
16-AA-0037
Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation
Participants currently recruited/enrolled
21-60 Years
NIAAA
16
15-I-0135
An open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ173 (leniolisib) in patients with APDS/PASLI (Activated
Completed Study; data analyses ongoing
12-75 Years
NIAID
16
15-C-0142
Acceptance and Commitment Training for Adolescents and Adults with Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain: A Phase III Clinical Trial
Completed Study; data analyses ongoing
16-59 Years
NCI
16
15-C-0138
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed Glioblastoma
Completed Study; data analyses ongoing
18-125 Years
NCI
16
15-C-0078
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
No longer recruiting/follow-up only
18-65 Years
NCI
16
15-AG-0123
Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function
Completed Study; data analyses ongoing
55-70 Years
NIA
Alzheimer
14-EI-0064
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions
Participants currently recruited/enrolled
1-125 Years
NEI
16
13-DK-0091
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir DF versus Tenofovir DF Monotherapy in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B
Completed Study; data analyses ongoing
18-125 Years
NIDDK
16
13-D-0033
Diagnosis and Treatment of Patients in Need of Third Molar Removal and Oral Specimen Acquisition
Participants currently recruited/enrolled
16-50 Years
NIDCR
16
13-C-0016
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults with Tumors with 1-3+ HER2/neu Expression
Completed Study; data analyses ongoing
18-125 Years
NCI
16
13-AG-0034
Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Bisnorcymserine (BNC), a Highly Selective Inhibitor of Butyrylcholinesterase, in Healthy Adult Volunteers
Completed Study; data analyses ongoing
55-125 Years
NIA
Alzheimer
12-HG-0022
Inherited Diseases, Caregiving, and Social Networks
Completed Study; data analyses ongoing
18-125 Years
NHGRI
Alzheimer
11-I-0057
Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy
Completed Study; data analyses ongoing
18-65 Years
NIAID
16
11-H-0134
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients
No longer recruiting/follow-up only
2-125 Years
NHLBI
16
11-D-0172
The Pathogenesis and Natural History of Sjogren's Syndrome
Participants currently recruited/enrolled
16-125 Years
NIDCR
16
11-C-0200
A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, with Cross-Over at Disease Progression
No longer recruiting/follow-up only
16-125 Years
NCI
16
10-AG-0423
A Pilot Study of Exendin-4 in Alzheimer's Disease
Completed Study; data analyses ongoing
60-125 Years
NIA
Alzheimer
09-I-0184
Studies in the Pathogenesis of Systemic Capillary Leak Syndrome
Participants currently recruited/enrolled
0-125 Years
NIAID
16
09-H-0199
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R agonist), Eltrombopag, in Patients with Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Completed Study; data analyses ongoing
18-125 Years
NHLBI
16
09-C-0024
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults
Completed Study; data analyses ongoing
12-26 Years
NCI
16
07-E-0012
Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
Completed Study; data analyses ongoing
2-125 Years
NIEHS
16
04-AR-0205
Progression of Spinal Fusion in Ankylosing Spondylitis
Completed Study; data analyses ongoing
18-125 Years
NIAMS
16
03-H-0170
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease (SCD) and Beta-Thalassemia
Participants currently recruited/enrolled
2-125 Years
NHLBI
16
03-AR-0131
Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
Completed Study; data analyses ongoing
18-125 Years
NIAMS
16
94-C-0074
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Participants currently recruited/enrolled
12-125 Years
NCI
16
91-AR-0196
Studies on the Natural History and Pathogenesis of Polymyositis, Dermatomyositis, and Related Diseases
Participants currently recruited/enrolled
16-125 Years
NIAMS
16